Tabuchi Norihiko, Akasaki Kenji, Tsuji Hiroshi
Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama 729-0292, Japan.
Biochem Biophys Res Commun. 2002 Jul 5;295(1):149-56. doi: 10.1016/s0006-291x(02)00642-3.
Lysosomal membrane glycoprotein termed LGP85 or LIMP II extends a COOH-terminal cytoplasmic tail of R459GQGSMDEGTADERAPLIRT478, in which an L475 I476 sequence lies as a di-leucine-based motif for lysosomal targeting. In the present study, we explored the role of the I476 residue in the localization of LGP85 to the endocytic organelles using two substitution mutants called I476A and I476L in which alanine and leucine are replaced at I476, respectively, and I476R477T478-deleted LGP85 called Delta 476-478. Immunofluorescence analyses showed that I476A and I476L are largely colocalized in intracellular organelles with an endogenous late endosomal and lysosomal marker, LAMP-1, but there were some granules in which staining for the LGP85 mutants was prominent, while Delta 476-478 is detected in LAMP-1-positive and LAMP-1-negative intracellular organelles, and on the cell surface. The subcellular fractionation studies revealed that I476A, I476L, and Delta 476-478 are different from wild-type LGP85 in the distribution of early endosomes, late endosomes, and lysosomes. I476A and I476L are present more in late endosomes than in the densest lysosomes, whereas wild-type LGP85 is mainly lysosomal. Substitution of I476 for A and L differentially modified the ratios of late endosomal to lysosomal LGP85. A major portion of Delta 476-478 resided in the light buoyant density fraction containing plasma membrane and early endosomes. Taken together, these results indicate that the existence of the 476th amino acid residue is essential for localization of LGP85 to late endocytic compartments. The fact that isoleucine but not leucine is in the 476th position is especially of importance in the proper distribution of LGP85 in late endosomes and lysosomes.
一种名为LGP85或LIMP II的溶酶体膜糖蛋白,其COOH末端细胞质尾巴为R459GQGSMDEGTADERAPLIRT478,其中L475 I476序列作为基于双亮氨酸的溶酶体靶向基序。在本研究中,我们使用两个替代突变体I476A和I476L(其中I476分别被丙氨酸和亮氨酸取代)以及缺失I476R477T478的LGP85(称为Delta 476 - 478),探讨了I476残基在LGP85定位于内吞细胞器中的作用。免疫荧光分析表明,I476A和I476L在很大程度上与内源性晚期内体和溶酶体标记物LAMP - 1共定位于细胞内细胞器中,但存在一些颗粒,其中LGP85突变体的染色很突出,而Delta 476 - 478在LAMP - 1阳性和LAMP - 1阴性细胞内细胞器以及细胞表面均有检测到。亚细胞分级分离研究表明,I476A、I476L和Delta 476 - 478在内体、晚期内体和溶酶体的分布上与野生型LGP85不同。I476A和I476L在晚期内体中的含量比在最致密的溶酶体中更多,而野生型LGP85主要存在于溶酶体中。将I476替换为A和L会不同程度地改变晚期内体与溶酶体中LGP85的比例。Delta 476 - 478的大部分存在于含有质膜和早期内体的轻浮力密度组分中。综上所述,这些结果表明第476位氨基酸残基的存在对于LGP85定位于晚期内吞区室至关重要。第476位是异亮氨酸而非亮氨酸这一事实,对于LGP85在晚期内体和溶酶体中的正确分布尤为重要。